安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- DUPIXENT® (dupilumab) Injection Instructions Support
Find videos and downloadable instructions for the two injection administration options available for DUPIXENT® (dupilumab), pre-filled syringe (200 mg or 300 mg) with needle shield for ages 6 months older, or pre-filled pen (200 mg or 300 mg) for ages 2+ years
- Dupixent® (dupilumab) injection - sanofi. us
Dupixent® (dupilumab) is an injection treatment for certain chronic conditions, including asthma, eczema, and nasal polyps
- Take Action With DUPIXENT® (dupilumab)
Learn more about DUPIXENT® (dupilumab), a prescription medicine FDA-approved to treat eight conditions See how DUPIXENT® may help Serious side effects can occur
- DUPIXENT® (dupilumab) HCP Website
DUPIXENT® (dupilumab) is a dual inhibitor of IL-4 and IL-13 signaling and is approved for 8 indications The mechanism of dupilumab action has not been definitively established Serious adverse reactions may occur Please see Important Safety Information and full Prescribing Information on website
- DUPIXENT. DUPIXENT - Food and Drug Administration
Administer subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel The upper arm can also be used if a caregiver administers the injection Rotate the
- Dupilumab: Uses, Dosage, Side Effects, Warnings - Drugs. com
Dupilumab is a subcutaneous injection that can be self-administered using a prefilled syringe or pen every 1 to 4 weeks, depending on the condition The brand name is Dupixent Dupilumab injection first gained FDA approval on March 28, 2017, under the brand Dupixent, made by Sanofi and Regeneron Pharmaceuticals under a collaborative agreement
- Press Release: Dupixent approved in the US as the only . . . - Sanofi
About Dupixent Dupixent (dupilumab) is an injection administered under the skin (subcutaneous injection) at different injection sites In adults with BP, Dupixent 300 mg is administered every other week after an initial loading dose, and in combination with a tapering course of oral corticosteroids Sanofi and Regeneron are studying
- Sanofi - Products - Specialty Care - DUPIXENT® (DUPILUMAB)® (dupilumab)
Those who continued dupilumab received supplemental treatment for psoriasis to improve associated symptoms Advise patients to report new-onset psoriasis symptoms If symptoms persist or worsen, consider dermatologic evaluation and or discontinuation of DUPIXENT
|
|
|